Incidence of Skeletal-related Events Over Time from Solid Tumour Bone Metastases Reported in Randomised Trials Using Bone-modifying Agents》.pdfVIP

Clinical Oncology 25 (2013) 435e444 Contents lists available at SciVerse ScienceDirect Clinical Oncology journal homepage: Original Article Incidence of Skeletal-related Events Over Time from Solid Tumour Bone Metastases Reported in Randomised Trials Using Bone-modifying Agents M. Poon, L. Zeng, L. Zhang, H. Lam, U. Emmenegger, E. Wong, G. Bedard, N. Lao, R. Chow, E. Chow Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada Received 24 August 2012; received in revised form 12 February 2013; accepted 13 February 2013 Abstract Aims: Skeletal-related events (SREs) in patients with bone metastases decrease a patient’s quality of life and functional status. Although bone-modifying agents have been found to reduce the time to first on-trial SRE and decrease the total incidence of SREs in randomised clinical trials, standard practice in the man- agement of bone metastases has changed concurrently. The purpose of this study was to investigate if advances in bone-targeted therapies have decreased the incidence of individual types of SREs and to delineate the trend of SREs. Materials and methods: A literature review was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials to identify phase III, randomised bisphosphonate and other bone-targeted therapy trials from 1980 to September 2011. For all studies, a mean year of enrolment ([start of enrolment þ end of enrolment]/2) was calculated. The incidences of SREs were tabulated and expressed as percentages of on-trial patients. Generalised linear mixed models were used to search for the trends of SREs over time for all placebo and intervention arms. Regression coefficients were interpreted as the